Cardiovascular and renal outcomes of glucagon-like peptide 1 receptor agonists among patients with and without type 2 diabetes mellitus: A meta-analysis of randomized placebo-controlled trials

Background: Multiple cardiovascular outcomes trials (CVOTs) have shown the efficacy of GLP-1RAs in reducing major adverse cardiovascular events (MACEs) for high-risk patients. However, some CVOTs failed to demonstrate cardiovascular benefits. Objectives: We analyzed the impact of GLP-1RA on cardiova...

Повний опис

Бібліографічні деталі

Автори:	Frederick Berro Rivera, Linnaeus Louisse A. Cruz, John Vincent Magalong, Jade Monica Marie J. Ruyeras, John Paul Aparece, Nathan Ross B. Bantayan, Kyla Lara-Breitinger, Martha Gulati
Формат:	Artigo
Мова:	Inglês
Опубліковано:	Elsevier 2024-06-01
Серія:	American Journal of Preventive Cardiology
Предмети:	Glucagon-like peptide 1 receptor agonists GLP-1RA Cardiovascular outcomes Renal outcomes MACE
Онлайн доступ:	http://www.sciencedirect.com/science/article/pii/S2666667724000473
Теги:	Додати тег Немає тегів, Будьте першим, хто поставить тег для цього запису!